TITLE

FERX AND JAPAN'S NCCRI COLLABORATE ON GENE THERAPY

PUB. DATE
August 2002
SOURCE
Worldwide Biotech;Aug2002, Vol. 14 Issue 8, p3
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the research collaboration between FeRx Inc. and National Cancer Center Research Institute in Japan in 2002, aimed at developing a novel tumor-targeting gene transfer approach.
ACCESSION #
7095467

 

Related Articles

  • Phase II/III Trials On for FeRx's Magnetic Technology. Webb, Marion // San Diego Business Journal;02/04/2002, Vol. 23 Issue 5, p7 

    Reports the PhaseII/III study testing of the magnetic targeted carrier technology of FeRx Inc. in San Diego, California. Examination of primary liver cancer patients; Approval by the Food and Drug Administration; Agreement between Syrrx Inc. and Pharmacia Corp.

  • FOCUS ON EUROPEAN NEWS.  // Applied Clinical Trials;Sep2002, Vol. 11 Issue 9, p74 

    Reports on developments in the pharmaceutical industry in Europe as of September 2002. Britannia Pharmaceuticals' regulatory approval for its apomorphine Parkinson's disease therapy, the APO-go Pen; FeRx Inc.'s orphan medicinal product designation for the EMEA for MTC-DOX for the treatment of...

  • Magnetic Drug Treatment Targets Cancerous Tumors. Webb, Marion // San Diego Business Journal;04/17/2000, Vol. 21 Issue 16, p3 

    Reports on FeRx Inc.'s development of chemotherapy-carrying magnetic particles directly targeting cancer cells. Use of magnetic targeted carriers; Reduction of debilitating side effects of chemotherapy.

  • Fe Rx Begins Testing Chemotherapy Delivery Technology on Liver Cancer.  // San Diego Business Journal;3/5/2001, Vol. 22 Issue 10, p23 

    Reports the initiation of Phase I/II trial to test the microscopic magnetic particles for patients with metastatic liver cancer by the FeRx Inc. in San Diego, California.

  • People.  // Nature Biotechnology;Apr2000, Vol. 18 Issue 4, p464 

    Focuses on promotions and appointments of several people related to biotechnology. Nomination of Vicente Anido to the board of directors FeRx Inc.; Appointment of Sally D. Bolmer as vice president regulatory affairs of Human Genome Sciences Inc.; Promotion of Stephen R. Davis to senior vice...

  • Struggling Biotech Mulls Closing Up Shop. Webb, Marion // San Diego Business Journal;5/10/2004, Vol. 25 Issue 19, p9 

    Reports on news and developments concerning the biotechnology industry in San Diego, California, as of May 10, 2004. FeRx Inc.'s decision to stop testing its flagship product, a technology to pull anti-cancer drugs to specific cancer sites; First quarter earnings of Sequenom Inc.; Resignation of...

  • Position- and base pair-specific comparison of p53 mutation spectra in human tumors: elucidation of relationships between organs for cancer etiology Lutz, Werner K.; Vamvakas, Spiros; Fekete, Tamas // Environmental Health Perspectives;Apr1998, Vol. 106 Issue 4, p207 

    A new approach to analyze the p53 mutation database of the European Molecular Biology Laboratory for a comparison of mutation spectra is described, with the aim of investigating organ specificity of etiological factors and putative organ-to-organ relationships in cancer pathogenesis. The number...

  • New understanding of cancer.  // Current Health 2;Apr85, Vol. 11 Issue 8, p3 

    We all fear the disease, but the good news is that new drugs and therapies, and earlier detection are improving the outlook for cancer victims.

  • Eat your grapefruit...  // Executive Health's Good Health Report;Jun92, Vol. 28 Issue 9, p1 

    Looks at a report from Michigan researchers in the `Journal of the National Cancer Institute' which notes that the injection of a modified form of citrus pectin, a substance which binds cell walls in oranges and grapefruit, appears to interfere with the way cancer cells cluster together and form...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics